Potential neuroprotective effects of acamprosate.
This article represents the proceedings of a symposium at the 2001 RSA Meeting in Montreal, Canada. The organizers were Barbara J. Mason and George F. Koob. Anita M. Goodman served as chair. The presentations were (1) Acamprosate inhibits alcohol withdrawal-induced neurotoxicity in organotypic hippocampal cultures, by John Littleton; (2) Acamprosate alteration of NMDA receptor-dependent synaptic transmission and synaptic plasticity, by George R. Siggins; (3) Acamprosate and glutamate during ethanol withdrawal, by Philippe De Witte; (4) Clinical evidence of protective CNS effects of acamprosate in alcohol-dependent individuals, by Barbara J. Mason.
Koob
George F
GF
Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California, USA.
Mason
Barbara J
BJ
De Witte
Philippe
P
Littleton
John
J
Siggins
George R
GR
D000077443:Acamprosate; D000427:Alcohol Deterrents / Q000494:pharmacology / Q000627:therapeutic use*; D000437:Alcoholism / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000523:psychology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D013654:Taurine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*
D000427:Alcohol Deterrents; D018696:Neuroprotective Agents; D013654:Taurine; D000077443:Acamprosate